Singh Biotechnology is a pre-clinical stage company that is developing a pipeline of highly selective novel single domain antibodies (sdAbs) around its proprietary technology for targeting intracellular proteins to treat a wide range of diseases including cancers, autoimmune and ophthalmic diseases.
